ArticleBreast cancer research : BCR2009
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Article in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2020Pooled it
- Mapping the Subtype-Specific PARP1 ADP-ribosylated Proteome in Breast Cancer Cells.bioRxiv : the preprint server for biology · 2025Article
- The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.Molecular cell · 2022Review
- Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.Life science alliance · 2021Article
- The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling.PloS one · 2021Article
- A Natural Quinazoline Derivative from Marine SpongeMarine drugs · 2019Article
- Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.Molecular cell · 2019Article
- Article
- Antiproliferative and Proapoptotic Activities of Marine SpongePharmacognosy magazine · 2017Article
- Silencing of ZRF1 impedes survival of estrogen receptor positive MCF-7 cells and potentiates the effect of curcumin.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- PARPs and ADP-Ribosylation: 50 Years … and Counting.Molecular cell · 2015Article
- DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.Breast cancer research and treatment · 2015Article
- Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.International journal of clinical and experimental pathology · 2015Article
- Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells.Breast cancer research and treatment · 2012Article
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.Genes & development · 2012Review
- Double-stranded DNA binding domain of poly(ADP-ribose) polymerase-1 and molecular insight into the regulation of its activity.The Journal of biological chemistry · 2011Article
- PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway.Molecular cell · 2010Article
- Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle arrest and cell death in breast cancer cells lacking BRCA1 and BRCA2 mutations and prevent the growth of tumors from xenografts of these cells in immunocompromised mice. These results suggest a potential broader utility of PARP-1 inhibitors in the treatment of breast cancer, although further mechanistic studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.